The US Supreme Court has agreed to review the dispute over "skinny labeling", which are thin drug labels. This decision concerns access to generic medicines. The dispute will be closely watched because of the potential implications for the availability of generic drugs. "Skinny labeling" allows generic drugs to list only part of the indications of the original drug. The Supreme Court's decision could affect how quickly generic drugs reach the market. A legal dispute arose between pharmaceutical companies and generic manufacturers. The result may change the rules for entry of cheaper alternatives to the US market.